Eom Pharmaceutical Hldgs Inc (OTC:IMUC)

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT:IMUC) announced the expansion of its relationship with Progenitor Cell Therapy, LLC (“PCT”), a subsidiary of NeoStem, Inc. (NASDAQ:NBS), for current good manufacturing practices (cGMP) services for ImmunoCellular’s dendritic cell-based vaccines. PCT currently manufactures ICT-121, a dendritic cell vaccine targeting CD133 cells, in a phase I clinical trial for recurrent glioblastoma multiforme (GBM) pursuant to a Services Agreement between the companies. PCT also manufactured phase II clinical supplies of ICT-107, a dendritic cell-based vaccine targeting six tumor-associated antigens for newly diagnosed GBM. Under this newly executed Services Agreement, PCT will manufacture clinical supplies of ICT-140, a dendritic cell vaccine targeting seven ovarian cancer antigens, using process improvements PCT will develop that can be applied to the manufacture of all ImmunoCellular’s current vaccine product candidates, ICT-107, ICT-121 and ICT-140. These process improvements are intended to increase quality, consistency, efficiency, and cost-effectiveness, and support ImmunoCellular’s vaccine manufacturing requirements for conducting potential phase III registration trials and for commercial manufacturing. PCT’s facilities are registered with the FDA as human cells, tissues, and cellular and tissue-based products (HCT/Ps) facilities, and maintain GMP-compliant quality systems.

    “Ensuring that ImmunoCellular has an established manufacturing process that can support pivotal registration programs and eventual commercial manufacturing for all our dendritic cell vaccines as they advance toward registration is foundational for building a leading cancer immunotherapy company”

“Ensuring that ImmunoCellular has an established manufacturing process that can support pivotal registration programs and eventual commercial manufacturing for all our dendritic cell vaccines as they advance toward registration is foundational for building a leading cancer immunotherapy company,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “We look forward to continuing our partnership with PCT, and are pleased to be making this investment in process enhancements now.”